Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice

Biomaterials

Volumn 34, Issue 16, 2013, Pages 4068-4077

  Wang, Yunfei ^a,b   Liu, Peifeng ^a   Qiu, Lihua ^a,b   Sun, Ying ^a   Zhu, Mingjie ^a   Gu, Liying ^a,b   Di, Wen ^a,b   Duan, Yourong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Gynecologic Oncology   (China)

Author keywords

Cisplatin; Cytotoxicity; Nanoparticles; Ovarian cancer; Targeting therapy

Indexed keywords

CELL-CYCLE ARREST; CIS-PLATIN; DRUG DISTRIBUTION; EPIDERMAL GROWTH FACTORS; OVARIAN CANCERS; PHYSICOCHEMICAL PROPERTY; TARGETING THERAPY; THERAPEUTIC EFFICIENCY;

CELL DEATH; COPOLYMERS; CYTOTOXICITY; DISEASES; EFFICIENCY; MAMMALS; MOTION PICTURE EXPERTS GROUP STANDARDS; PLATINUM COMPOUNDS; TOXICITY;

NANOPARTICLES;

CISPLATIN; EPIDERMAL GROWTH FACTOR; METHOXY POLYETHYLENE GLYCOL POLYLACTIC CO GLYCOLIC ACID POLYLYSINE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; EPIDERMAL GROWTH FACTOR; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; OVARIAN NEOPLASMS; POLYESTERS; POLYETHYLENE GLYCOLS; POLYLYSINE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84874989258     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.033     Document Type: Article

References (22)

1. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011, 61:183-203.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Gennari R., Audisio R.A. Surgical removal of the breast primary for patients presenting with metastases - where to go?. Cancer Treat Rev 2009, 35:391-396.
4. Uchino H., Matsumura Y., Negishi T., Koizumi F., Hayashi T., Honda T., et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Brit J Cancer 2005, 93:678-687.
5. Gu J.L., Su S.S., Li Y.S., He Q.J., Shi J.L. Hydrophilic mesoporous carbon nanoparticles as carriers of hydrophobic anti-cancer drugs for sustained release. J Phys Chem Lett 2010, 1:3446-3450.
6. Du J., Shi Q.S., Sun Y., Liu P.F., Zhu M.J., Du L.F., et al. Enhanced delivery of monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic)-poly l-lysine nanoparticles loading platelet-derived growth factor BB small interfering RNA by ultrasound and/or microbubbles to rat retinal pigment epithelium cells. J Gene Med 2011, 13:312-323.
7. Du J., Shi Q.S., Sun Y., Liu P.F., Zhu M.J., Wang C.H., et al. Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing. Int J Mol Sci 2012, 13:516-533.
8. Yin P.H., Wang Y., Qiu Y.Y., Hou L.L., Liu X., Qin J.M., et al. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomedicine 2012, 7:3961-3969.
9. Liu P.F., Wang H.B., Wang Q., Sun Y., Shen M., Zhu M.J., et al. cRGD conjugated mPEG-PLGA-PLL nanoparticles for SGC-7901 gastric cancer cells-targeted delivery of fluorouracil. J Nanosci Nanotechnol 2012, 12:4467-4471.
10. Liu P.F., Yu H., Sun Y., Zhu M.J., Duan Y.R. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 2012, 33:4403-4412.
11. Liu P.F., Qin L.B., Wang Q., Sun Y., Zhu M.J., Shen M., et al. cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials 2012, 33:6739-6747.
12. Sheng Q., Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Brit J Cancer 2011, 104:1241-1245.
13. Liu P.F., Li Z.H., Zhu M.J., Li Y.G., Wang H.Z., Duan Y.R. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J Mater Sci Mater Med 2010, 21:551-556.
14. n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett 2005, 5:2050-2057.
15. Choi K.Y., Yoon H.Y., Kim J.H., Bae S.M., Park R.W., Kang Y.M., et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5:8591-8599.
16. Bhirde A.A., Kapoor A., Liu G., Lglesias-Bartolome R., Jin A., Zhang G.F., et al. Nuclear mapping of nanodrug delivery systems in dynamic cellular environments. ACS Nano 2012, 6:4966-4972.
17. Philips M.A., Gran M.L., Peppas N.A. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010, 5:143-159.
18. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
19. Xiao L., Xiong X., Sun X., Zhu Y., Yang H., Chen H., et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
20. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
21. Konishi M., Tabata Y., Kariya M., Suzuki A., Mandai M., Nanbu K., et al. In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release 2003, 92:301-313.
22. Ding D., Zhu Z.S., Li R.T., Li X.L., Wu W., Jiang X.Q., et al. Nanosphere-incorporated implantable hydrogel as a trans-tissue drug delivery system. ACS Nano 2011, 5:2520-2534.